PCVX vs. ROIV: Vaxcyte vs. Roivant Sciences Stock Comparison
How do Vaxcyte (PCVX) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Vaxcyte (PCVX) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | PCVX | ROIV |
|---|---|---|
| Name | Vaxcyte Inc. | Roivant Sciences Ltd. |
| Country/Region | United States | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.11 billion USD | 28.08 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 12, 2020 | December 8, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Total Return (1Y) | 59.00% | 96.75% |
| Total Return (3Y, Annualized) | 11.29% | 68.04% |
| Total Return (5Y, Annualized) | 21.60% | 36.73% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Volatility (1Y, Annualized) | 56.01% | 47.99% |
| Beta (5Y) | 1.26 | 1.17 |
| Max Drawdown (5Y) | -76.22% | -79.22% |
| Avg. Volume (3M) | 2.12M | 7.82M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Sharpe Ratio (1Y) | 0.98 | 1.93 |
| Sortino Ratio (1Y) | 1.76 | 4.03 |
Profitability
ROE (TTM)
Both Vaxcyte (PCVX) at -42.68% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-42.68%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- PCVX
- -42.68%
- Q1
- -64.05%
- Min
- -167.77%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Vaxcyte (PCVX) at 0.00% and Roivant Sciences (ROIV) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
Profitability Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| ROE (TTM) | -42.68% | -8.52% |
| ROA (TTM) | -24.98% | -16.28% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | -25,408.11% |
| Gross Margin (TTM) | 0.00% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Roivant Sciences (ROIV) reports revenue growth of -71.57%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.
EPS Growth
Neither Vaxcyte (PCVX) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Revenue Growth (YoY) | -- | -71.57% |
| Revenue Growth (3Y CAGR) | -- | -36.01% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.56
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- PCVX
- 4.56
- Q1
- 2.47
- Min
- 0.10
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Vaxcyte (PCVX) at 0.09 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- PCVX
- 0.09
- Q1
- 0.02
- Min
- 0.00
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Current Ratio (MRQ) | 4.56 | 16.72 |
| Debt / Equity (MRQ) | 0.09 | 0.02 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Vaxcyte (PCVX) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Vaxcyte (PCVX) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Vaxcyte (PCVX) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- PCVX
- --
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
P/S Ratio (TTM)
A sales-based read is only available for Roivant Sciences (ROIV), whose P/S ratio of 3,728.61 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- PCVX
- --
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.83
- Max
- 13.53
- Q3
- 6.54
- PCVX
- 3.83
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | PCVX | ROIV |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | -- | 3,728.61 |
| P/B Ratio (MRQ) | 3.83 | 6.64 |
| Free Cash Flow Yield (TTM) | -5.24% | -3.98% |